Le Lézard
Classified in: Health, Science and technology
Subjects: Event, Product/Service, Webcast

Orca Bio to Present New Clinical Data on Orca-T at the 63rd American Society of Hematology Annual Meeting


Orca Bio, a clinical-stage biotechnology company developing purified, high-precision cell therapies for cancer, autoimmune and genetic blood disorders, today announced that new data will be presented from a single-center Phase 2 trial and a multi-center Phase 1b trial at the American Society of Hematology (ASH) Annual Meeting. Specifically, pooled data from patients treated with Orca-T, an investigational high-precision cell therapy product being studied in patients with hematologic malignancies, will be shared in an oral presentation. Additionally, results of Orca-T in a subset of patients with myelofibrosis from those same trials will be shared in a poster presentation.

"Our clinical experience with Orca-T has grown significantly over the past year and we are pleased to present data on an expanded group of patients who now have one year of follow-up with Orca-T," said Ivan Dimov, Ph.D., cofounder and chief executive officer of Orca Bio. "We look forward to presenting these important findings at ASH as we continue to work to deliver on our promise of maximizing patient survival while minimizing the compromise of toxicities to enable better outcomes."

The ASH abstracts are now available at www.hematology.org.

Details of the Orca Bio presentations follow:

Oral Presentation:

Orca-T Results in High GVHD-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies: Results of a Single Center Phase 2 and a Multicenter Phase 1b Study
Abstract Number: 98
Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Prevention of graft vs. host disease after allogeneic hematopoietic cell transplantation
Presentation Date: Saturday, December 11, 2021, at 9:45 AM EST
Location: Georgia World Congress Center, B302-B303

Poster Presentation:

Outcomes for Myelofibrosis Patients Following Myeloablative Allogeneic Stem Cell Transplantation Using the Orca-T Graft from HLA-Matched Related and Unrelated Donors
Abstract Number: 1819
Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster I
Presentation Date: Saturday, December 11, 2021, at 5:30 PM - 7:30 PM EST
Location: Georgia World Congress Center, Hall B5

About Orca-T
Orca-T is an investigational high-precision allogeneic cellular therapy consisting of infusions containing regulatory T-cells, conventional T-cells and CD34+ stem cells derived from peripheral blood from either related or unrelated matched donors. Orca-T has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration and is being studied to treat multiple hematologic malignancies.

About Orca Bio
Orca Bio is a clinical-stage biotechnology company developing purified, high-precision cell therapies for cancer, autoimmune and genetic blood disorders. Our investigational therapies are designed to deliver better survival rates with dramatically fewer risks than standard allogeneic stem cell transplants, like graft versus host disease and other debilitating transplant-related toxicities. At Orca Bio, we hope to not only replace patients' blood and immune systems with healthy ones, but restore their quality of life. For more information, visit www.orcabio.com and follow Orca Bio on Twitter: @orcabio.


These press releases may also interest you

at 17:10
MetaGoons, a pioneering Metaverse ecosystem and development platform, has announced its completion of a $2 million seed round. The company also revealed that it has partnered with Team Pacquiao GG, legendary boxer and Philippines Senator Manny...

at 17:08
Pluribus Technologies Corp.  (the "Company") today announced that it has granted options to purchase up to 788,269 common shares as part of the overall remuneration and incentive program for its directors, officers and employees. The options expire...

at 17:05
Seres Therapeutics, Inc. , a leading microbiome therapeutics company, today announced the publication in the New England Journal of Medicine (NEJM) of data from its Phase 3 ECOSPOR III study evaluating SER-109, an investigational oral microbiome...

at 17:00
Green Roads, a subsidiary of The Valens Company Inc.  ) (the "Company" "The Valens Company" or "Valens"), announces the launch of its first-ever brand campaign "Own the Day". The campaign celebrates Green Roads' products and their ability to help...

at 17:00
At a signing ceremony held on January 18 in Hangzhou, Hikvision announced that it becomes the Official Intelligent IoT & Big Data Sponsor of the 19th Asian Games Hangzhou 2022 and the 4th Asian Paralympic Games. As a sponsor, Hikvision will provide...

at 16:47
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA, SOUTH AFRICA, NEW ZEALAND, JAPAN OR THE UNITED STATES, OR ANY OTHER...



News published on 4 november 2021 at 10:25 and distributed by: